NFKB1 and nonpapillary renal cell carcinoma: With respect to ccRCC biology, possible further inhibition mechanisms could include e.g. interactions with the NF-κB pathway (Gurova et al. 2005), PBRM1 (Macher-Goeppinger et al. 2015) and members of the thioredoxin family (Ueno et al. 1999).